{"name":"Newron Pharmaceuticals SPA","slug":"newron-pharmaceuticals-spa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Safinamide (as add-on therapy)","genericName":"Safinamide (as add-on therapy)","slug":"safinamide-as-add-on-therapy","indication":"Parkinson's disease","status":"phase_3"}]}],"pipeline":[{"name":"Safinamide (as add-on therapy)","genericName":"Safinamide (as add-on therapy)","slug":"safinamide-as-add-on-therapy","phase":"phase_3","mechanism":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A).","indications":["Parkinson's disease","Major depressive disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRDRSbEN0dDlHdHFfaUxoNjdKc0RZMDFqbzQtUDFmNXlRano0U2tYQWFKX1A4WUxjeTItSnJsckFGcXBNVTc1WDhVMjJmOHhEY2tqeFlpNlNWRFJJTFRiQzV6bW41alRrRG9EdHlZeVFwQVZnTkhXamtLRUVKMHhkNVpVRDJXTGRfTk9aZUhQWTkzV2pXdXpzaTMwbnFENGh3SThPQmdVcXE?oc=5","date":"2026-01-14","type":"pipeline","source":"Meyka","summary":"Pre-market: NP5.DE Newron Pharmaceuticals XETRA -9.85% 14 Jan 2026: catalyst watch - Meyka","headline":"Pre-market: NP5.DE Newron Pharmaceuticals XETRA -9.85% 14 Jan 2026: catalyst watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNSXBvSjJ0ckFhWDFIZ2k2dENaVkowZGQ3enVNNHpITHNoamVKREEzSXgzSmRJSUEzOXA1S01sSmttMHlUUjNCczJ4TklrSHVoYmlwMm92QnRtT2drNHVBVEM2Z0pxbExKdFdJSnkwSV9IM1RmNm1KcU1sQkVveERDcUpsdTdiTFNGbWJub0FaQ2NiU1ZaNnNQR0ZXZzhNQUYzbjFuZFBLNG5vSko4eUd1TTNfSkxnQWkyZ1hIU2dnMDllQlZWalNMWHNvZ2RHOG9vSFhST09Wc3gwSEkyZjdROVRBcS1GTUk0VHp6U1U2Vlo5YU5qc2xNT0F2LS1HVC1pVTR3NFZsNE13eVJUUThVRGtjMXVTOWs?oc=5","date":"2026-01-07","type":"trial","source":"BioSpace","summary":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - BioSpace","headline":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treat","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"pipeline","source":"simplywall.st","summary":"What You Need To Know About The Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade Today - simplywall.st","headline":"What You Need To Know About The Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSmlRS1JITXhxQ0JRbHJndnJQei0tTkhwWG1zTWlxZXdnbEdZUnNycW9hcTVsSFliNTN6b2J3NnJ2SGZObkVtOV91NWRJTjVuV3o4NEs0c003UDlnek9hLW9rSjJIS3hqV2ktN25MY01XVUc3MWR3ZFM4WTZSclNVdmFQcFBJZjJH?oc=5","date":"2025-12-15","type":"pipeline","source":"Yahoo Finance","summary":"Time To Worry? Analysts Just Downgraded Their Newron Pharmaceuticals S.p.A. (VTX:NWRN) Outlook - Yahoo Finance","headline":"Time To Worry? Analysts Just Downgraded Their Newron Pharmaceuticals S.p.A. (VTX:NWRN) Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5TbmkzZ05Pd0lKVmRqZlNtaWlYdTF6WU9kRWFVcVR6aEtqeTlYMFpWeG01ZVotTjVOWThKQTRPaGlkMTg4Qk4tWXpjV2ZNczA3MWEtM3JSQzNEdnZuRG9Ia3RqVEpPOFJSX1dzQ3lUbl9sdU1CWjdsWDhn?oc=5","date":"2025-04-29","type":"regulatory","source":"CHEManager","summary":"Newron Pharmaceuticals SpA - CHEManager","headline":"Newron Pharmaceuticals SpA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBKdHlVNVNwUVNpZDFKRldBSnducFpCQlkwdnVmTFRLS2xsRlBPYnBlUHBBRHVaME81VTJoZ3I4NE5QTEltVHY4dHphV21tNFpsdGM0T0dwNlpKS0dyMmNCQ2NMT29JdjRZWUg3bFBnT0NjNEVrWjZZS2Y3aTg1UQ?oc=5","date":"2025-01-10","type":"pipeline","source":"Pharmaceutical Technology","summary":"Newron and Myung In Pharm sign agreement for evenamide development - Pharmaceutical Technology","headline":"Newron and Myung In Pharm sign agreement for evenamide development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNLWV6UTFVSm5ZUC1zNmxsMVpvbFF3MExENFZqZVZIUmVVSFlYVUgxaHdGaFF3NVZuaVhjMmJvWHBHVFlvZWRRX2FSRklLcVpNWm9LLW94UDdfUzNpSENFRlJRRHRMVk5TRTl5am1jeGV1NDhIUUkxUDBRWGs1M0tmX0JwanI5ajk0dVd1UVRBQTAwOWJxaWtmaWVNNHVPZ3h5Y0U0NXJQUWR1aDhQRUtNYXFabzV3WmNSSUN2NjViZjM0V0FVNG5BYTZHbHVyMlhCYzg2bGxfQzN5S1lzakpRa0FLM2JtTmJpZFN2a2x4VlUtbVNtSEU2QlJjdw?oc=5","date":"2024-12-13","type":"deal","source":"BioSpace","summary":"Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories - BioSpace","headline":"Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPZkNENVNFekJFOGpRTWtWakRtNlBMaldaRG1zUWFYakFDN3lSSld1WlQ4M2RHUEZSS09aek1oSDJJMlQ4T0puNjdMOVhXY1Y4UFFzeUtLS0lTbGdrOFZfWkh1LWtxQ0VxNURCRU1sQVRSRExMTE1HRVlBSy1rQndUb3VMTk44X0ItZ21ZajRkcw?oc=5","date":"2023-06-25","type":"pipeline","source":"marketscreener.com","summary":"Newron Pharmaceuticals S.p.A.: Target Price Consensus and Analysts Recommendations | NWRN | IT0004147952 - marketscreener.com","headline":"Newron Pharmaceuticals S.p.A.: Target Price Consensus and Analysts Recommendations | NWRN | IT0004147952","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE1US3FyQXN2Z3lvX01jTDU0Mk9nVnFYN1FIWDRKWGdCMGxGNUE0V0p2d1N2eXdvNnpBYkgyb1I0UFU4X1VyN2dubk00TmxUQTlEeE55TkNOVUxGejM4YkhPNXVGMzQ?oc=5","date":"2022-08-21","type":"pipeline","source":"TradingView","summary":"NWRN Forecast — Price Target — Prediction for 2027 - TradingView","headline":"NWRN Forecast — Price Target — Prediction for 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE8ySElnRDlzVVFPUWUzUEk2RUIyMmJQWWQwTjlvaUNZc3BrOTNDS29ZMzJhcXd4TFU1VjU5RC1Dd0xQWUNlVVUtcW8yMEQ?oc=5","date":"2020-12-14","type":"deal","source":"StockInvest.us","summary":"Newron Pharmaceuticals S.p.a Stock Price Forecast. Should You Buy NWRN.SW? - StockInvest.us","headline":"Newron Pharmaceuticals S.p.a Stock Price Forecast. Should You Buy NWRN.SW?","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}